# Magnesium Disorders: The Forgotten Electrolyte

## Executive Summary

Magnesium disorders are frequently underrecognized. Hypomagnesemia affects **2–15% of hospitalized patients** and up to **65% of ICU patients**. Magnesium serves as cofactor for over 300 enzymatic reactions and plays crucial roles in cellular energy metabolism, protein synthesis, and ion channel function. Understanding its relationships with potassium and the PTH-calcium axis proves essential for managing complex electrolyte disorders.

### Physiologic Role and Homeostasis

Fourth most abundant cation in the body, second most prevalent intracellular cation (after potassium). Total body Mg: ~25 g (1,000 mmol) — **99% intracellular** (60% bone, 39% soft tissues, only 1% in ECF). This distribution explains why serum levels may not reflect total body stores.

**Normal serum Mg:** 1.8–2.4 mg/dL (0.75–1.0 mmol/L). Kidneys filter ~2,400 mg daily with 95% reabsorbed:

- **20%** proximal tubule
- **60%** thick ascending limb of Henle (via claudin-16 and claudin-19)
- **10%** distal convoluted tubule (via TRPM6 channels)

The Mg-ATP complex is the physiologically active form of ATP. Magnesium modulates Na-K-ATPase, calcium channels, cardiac conduction, neuromuscular function, and vascular tone.

## Hypomagnesemia: Pathophysiology, Diagnosis, and Management

### Nutritional and Absorptive Disorders

#### Chronic Alcohol Use Disorder

One of the most common causes, affecting an estimated **30% of hospitalized alcoholic patients**. Multiple mechanisms:

- Direct intestinal epithelial damage and altered TRPM6/TRPM7 transporter expression
- Alcohol-induced GI inflammation reducing absorptive surface area
- Poor dietary intake + increased renal losses from alcohol-induced diuresis
- Alcohol withdrawal significantly increases Mg requirements (enhanced sympathetic activity)

**Clinical Pearl:** Adequate magnesium stores may reduce the likelihood of withdrawal-related seizures. Aggressive replacement during detoxification is warranted — often requiring substantially higher doses than predicted by serum levels alone. Malabsorption Syndromes

Chronic diarrhea (secretory \> osmotic), inflammatory bowel disease, short bowel syndrome, chronic pancreatitis. Post-surgical states: extensive small bowel resection, bariatric surgery (Roux-en-Y, biliopancreatic diversion).

Protein-Energy Malnutrition

Refeeding syndrome risk: rapid carbohydrate administration increases cellular Mg demands while depleted stores cannot meet requirements, potentially precipitating severe hypomagnesemia.

### Renal Magnesium Wasting

- **Gitelman syndrome:** NCCT gene mutations → hypomagnesemia, hypokalemia, hypocalciuria
- **Bartter syndrome variants:** Mg wasting with volume depletion
- **Loop diuretics:** Inhibit Mg reabsorption in thick ascending limb
- **Thiazide diuretics:** Affect DCT; chronic use produces a “Gitelman phenocopy”
- **Other medications:** Aminoglycosides, calcineurin inhibitors, cisplatin, cetuximab

### Endocrine and Metabolic Causes

- **Diabetes mellitus:** Osmotic diuresis from glucosuria + diabetic nephropathy + insulin resistance effects
- **Hyperaldosteronism:** Enhanced distal tubule flow rates → increased renal Mg excretion
- **Hyperthyroidism:** Increased renal Mg clearance + reduced intestinal absorption

## Table 1: Causes of Hypomagnesemia by Category

| Category | Specific Causes | Key Clinical Features |
|----|----|----|
| **Nutritional/GI** | Chronic alcohol use disorder | Multiple nutrient deficiencies, withdrawal risk |
|  | Protein-energy malnutrition | Refeeding syndrome risk, cachexia |
|  | Inflammatory bowel disease | Active inflammation, diarrhea |
|  | Short bowel syndrome | Post-surgical, malabsorption |
|  | Chronic diarrhea | Volume losses, secretory vs osmotic |
|  | Bariatric surgery | RYGB, biliopancreatic diversion |
| **Renal Losses** | Loop diuretics | Dose-dependent, concurrent hypokalemia |
|  | Thiazide/thiazide-like diuretics | Gitelman-like syndrome |
|  | Aminoglycosides | Nephrotoxicity, duration-dependent |
|  | Calcineurin inhibitors | Transplant patients, vasoconstriction |
|  | Proton pump inhibitors | Long-term use, intestinal transport inhibition |
|  | Gitelman syndrome | Genetic, hypocalciuria |
|  | Primary aldosteronism | Hypertension, hypokalemia |
| **Endocrine** | Diabetes mellitus | Osmotic diuresis, poor glycemic control |
|  | Hyperthyroidism | Increased clearance, hypermetabolism |
|  | Primary hyperparathyroidism | Hypercalciuria, bone turnover |
| **Medications** | Cisplatin, cetuximab | Cumulative dose-dependent |
|  | Foscarnet, pentamidine | Antiviral/anti-pneumocystis, tubular toxicity |

## Clinical Manifestations and Diagnostic Approach

### Clinical Manifestations

Often asymptomatic until Mg \<1.2 mg/dL (0.5 mmol/L). Early: fatigue, weakness, irritability, muscle cramps. Progressive: Chvostek and Trousseau signs, muscle fasciculations (facial muscles are early/specific). Severe: tetany, seizures, altered mental status.

#### Cardiovascular Complications

- Atrial and ventricular arrhythmias; digitalis toxicity enhanced
- **Torsades de pointes:** Most serious complication, especially with concurrent hypokalemia or prolonged QT
- Coronary artery spasm, increased peripheral vascular resistance

### Laboratory Assessment

**Serum Mg limitations:** Up to **30%** of total body Mg may be lost before serum levels decrease.

**Magnesium tolerance test:** 0.2 mmol/kg IV MgSO4, measure 24h urine. Retention \>50% indicates deficiency (gold standard but limited clinical utility).

**Fractional excretion of Mg:** FE_(Mg) = (U_(Mg) × S_(Cr)) / (0.7 × S_(Mg) × U_(Cr)) × 100. In hypomagnesemia: **\>2% = renal wasting**; \<2% = extrarenal losses or inadequate intake.

### Table 3: Diagnostic Workup for Hypomagnesemia

| Category | Tests | Interpretation |
|----|----|----|
| **Initial Labs** | Fasting serum Mg, BMP, albumin, ionized Ca | \<1.8 mg/dL diagnostic; check concurrent electrolytes |
| **Concurrent** | K, PO4, 25-OH Vit D, intact PTH | 60% have concurrent hypoK; PTH suppressed in severe deficiency |
| **Renal** | 24h urine Mg, FE_(Mg), spot urine Mg/Cr ratio, Cr/eGFR | FE_(Mg) \>2% = renal wasting; 24h \<120 mg/day appropriate in deficiency |
| **Specialized** | Mg tolerance test, genetic testing | Gold standard for body stores; suspected inherited disorders |
| **History** | Medications (diuretics, PPIs, antibiotics), alcohol, nutrition, family hx | Identify modifiable causes |
| **Exam** | Reflexes, Chvostek/Trousseau, CV evaluation, malabsorption signs | Neuromuscular hyperexcitability, arrhythmias |

## Treatment Strategies

### Oral Magnesium Supplementation

| Formulation | Elemental Mg Content | Absorption | Notes |
|----|----|----|----|
| **Mg oxide** | 60% | **Poor (4%)** | Frequently causes diarrhea; not recommended |
| **Mg citrate** | 16% | Good | Widely available; osmotic laxative effect |
| **Mg gluconate** | 5% | Good | Well tolerated, low elemental content |
| **Mg glycinate/bisglycinate** | Variable | **Excellent** | Optimal absorption with minimal GI side effects |

**Dosing:** 400–800 mg elemental Mg daily, divided into 2–3 doses. Treatment duration: weeks to months depending on etiology.

### Parenteral Magnesium Therapy

#### Acute Severe Hypomagnesemia

1–2 g (4–8 mmol) MgSO4 in 50–100 mL NS IV over 1–2 hours, then 6 g (24 mmol) over 24 hours by continuous infusion. Monitor serum levels every 6–8 hours.

#### Chronic Parenteral Therapy

Weekly or twice-weekly infusions of 2–4 g MgSO4 for patients with ongoing losses or malabsorption.

**Warning — Torsades de Pointes:** Life-threatening arrhythmias require immediate IV Mg **regardless of serum levels**. Standard protocol: 2 g MgSO4 IV push over 1–2 minutes, then reassess.

## Hypermagnesemia: Recognition and Management

### Etiology

Rarely occurs with normal renal function. CKD stages 4–5 (eGFR \<30) significantly impairs Mg elimination. Common sources: excessive IV MgSO4 (eclampsia treatment), Mg-containing antacids/laxatives in renal impairment, Epsom salt ingestion.

### Table 2: Causes of Hypermagnesemia

| Category | Specific Causes | Risk Factors |
|----|----|----|
| **Renal** | CKD stages 4–5 | eGFR \<30 mL/min/1.73m² |
|  | AKI | Oliguria, volume overload |
|  | ESRD | Dialysis patients between sessions |
| **Exogenous** | IV MgSO4 overdose | Eclampsia treatment, cardiac arrest |
|  | Mg-containing antacids | Chronic use in renal dysfunction |
|  | Mg-containing laxatives | Cathartic abuse, renal impairment |
|  | Epsom salt ingestion | Therapeutic or intentional overdose |
| **Endocrine** | Primary hyperparathyroidism | Bone resorption, hypercalcemia |
|  | Hypothyroidism, Addison’s disease | Reduced clearance |

### Threshold Effects and Clinical Correlation

| Serum Mg (mg/dL) | Serum Mg (mmol/L) | Clinical Manifestations |
|----|----|----|
| **4.8–6.0** | 2.0–2.5 | Generally asymptomatic; mild sedation possible |
| **6.0–10.8** | 2.5–4.5 | Absent DTRs, weakness, confusion |
| **10.8–15.6** | 4.5–6.5 | Respiratory depression, complete heart block |
| **\>15.6** | \>6.5 | Cardiac arrest, coma |

**Clinical Pearl:** Deep tendon reflexes disappear at Mg 7–10 mg/dL — a **reliable early indicator** of toxicity. Monitor DTRs in any patient receiving IV Mg.

### Management of Hypermagnesemia

#### Severe Symptomatic

1.  **IV calcium:** 1–2 g calcium chloride or 2–3 g calcium gluconate for functional antagonism. Effects appear within minutes but are temporary.
2.  **Enhanced elimination:** NS + furosemide 40–80 mg IV (adequate renal function). Promotes Mg excretion.
3.  **Hemodialysis:** For severe hyperMg with renal failure. Clearance rates approach 100 mL/min. CRRT for hemodynamically unstable patients.
4.  **Supportive care:** Mechanical ventilation if respiratory depression; vasopressors for severe hypotension.

## Special Clinical Considerations

### Mg-Containing Laxatives in CKD

**Warning:** CKD stages 4–5 patients face substantial hyperMg risk from Mg-containing laxatives. A single dose of magnesium citrate contains ~1.75 g elemental Mg — equivalent to normal daily renal filtration load. Renal Mg elimination may be reduced by **75% or more** in advanced CKD.

**Preferred laxatives in CKD:** PEG-based (MiraLAX), docusate sodium, senna/bisacodyl cautiously, lubiprostone, linaclotide. Avoid all Mg-containing products (milk of magnesia, Mg citrate, Epsom salts).

### Proton Pump Inhibitors and Hypomagnesemia

Incidence: **5–10% of long-term users**. Mechanism: impaired intestinal Mg absorption via TRPM6/TRPM7 channel inhibition + altered gastric pH affecting Mg solubility. Dose-dependent and duration-related (typically months to years before manifestation).

Suspect in long-term PPI users with neuromuscular symptoms, especially with concurrent hypoK and hypoCa resistant to replacement. Consider H2 receptor antagonists as alternatives.

### Diuretics and Magnesium Homeostasis

#### Loop Diuretics

Inhibit NKCC2 in the thick ascending limb (where 60% of Mg is reabsorbed). Furosemide has greatest Mg-wasting potential. Losses increase proportionally with dose; patients on \>80 mg daily furosemide equivalent are at particular risk.

#### Thiazide Diuretics

Affect NCCT in the DCT. Chlorthalidone and indapamide (longer half-lives) may produce more sustained Mg losses. Chronic use produces a “Gitelman syndrome phenocopy”: hypoMg, hypoK, hypocalciuria.

**Monitoring:** Baseline Mg, then at 1–2 weeks, then every 3–6 months. More frequent with dose changes or addition of other Mg-depleting drugs.

**Potassium-sparing diuretics** (amiloride, spironolactone) may partially mitigate Mg losses but do not completely prevent depletion.

## Electrolyte Interrelationships: Mg, K, and the Ca-PTH Axis

### Magnesium-Potassium Interactions

One of the most clinically significant electrolyte interactions. Approximately **60% of hypoMg patients have concurrent hypoK**.

- Mg deficiency reduces Na-K-ATPase activity → cellular K losses + impaired renal K reabsorption
- Mg depletion enhances K secretion in the collecting duct (increased K channel activity + altered mineralocorticoid sensitivity)

**Clinical Pearl:** **Hypokalemia is refractory to potassium supplementation when significant hypomagnesemia coexists.** Successful K repletion requires concurrent Mg correction. Always check Mg when treating resistant hypoK. Optimal management involves **simultaneous correction** of both deficits. Standard protocol: 2–4 g IV MgSO4 with 40–80 mEq KCl, monitoring every 6–8 hours.

### Magnesium-Calcium-PTH Relationships

- **Mild-moderate hypoMg:** Stimulates PTH release (secondary hyperparathyroidism)
- **Severe hypoMg (\<1.0 mg/dL):** Paradoxically **suppresses PTH secretion** (impaired synthesis and release)
- **PTH resistance:** HypoMg reduces target organ responsiveness to PTH in both bone and kidney → functional hypoparathyroidism
- **Vitamin D metabolism:** Mg is cofactor for 25-OH-D-1alpha-hydroxylase → deficiency impairs activation of 1,25(OH)2D3

**Warning:** Hypocalcemia in the setting of magnesium deficiency is typically **refractory to calcium supplementation** until magnesium stores are repleted. Prioritize Mg replacement. Vitamin D supplementation may also be necessary.

## References and Suggested Reading

1.  de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. *Physiol Rev.* 2015;95(1):1-46. [PMID: 25540137](https://pubmed.ncbi.nlm.nih.gov/25540137/)
2.  Cheungpasitporn W, Thongprayoon C, Qian Q. Dysmagnesemia in hospitalized patients: prevalence and prognostic importance. *Mayo Clin Proc.* 2015;90(9):1202-1213. [PMID: 26250725](https://pubmed.ncbi.nlm.nih.gov/26250725/)
3.  Whang R, Ryder KW. Frequency of hypomagnesemia and hypermagnesemia. *JAMA.* 1990;263(22):3063-3064. [PMID: 2342219](https://pubmed.ncbi.nlm.nih.gov/2342219/)
4.  Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. *J Am Soc Nephrol.* 2007;18(10):2649-2652. [PMID: 17804670](https://pubmed.ncbi.nlm.nih.gov/17804670/)
5.  Hoorn EJ, Zietse R. Disorders of calcium and magnesium balance: a physiology-based approach. *Pediatr Nephrol.* 2013;28(8):1195-1206. [PMID: 23142866](https://pubmed.ncbi.nlm.nih.gov/23142866/)
6.  Agus ZS. Hypomagnesemia. *J Am Soc Nephrol.* 1999;10(7):1616-1622. [PMID: 10405219](https://pubmed.ncbi.nlm.nih.gov/10405219/)
7.  Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. *Aliment Pharmacol Ther.* 2012;36(5):405-413. [PMID: 22762246](https://pubmed.ncbi.nlm.nih.gov/22762246/)
8.  Saris NE, Mervaala E, Karppanen H, et al. Magnesium: an update on physiological, clinical and analytical aspects. *Clin Chim Acta.* 2000;294(1-2):1-26. [PMID: 10727669](https://pubmed.ncbi.nlm.nih.gov/10727669/)
9.  Van Laecke S. Hypomagnesemia and hypermagnesemia. *Acta Clin Belg.* 2019;74(1):41-47. [PMID: 30220246](https://pubmed.ncbi.nlm.nih.gov/30220246/)
10. Topf JM, Murray PT. Hypomagnesemia and hypermagnesemia. *Rev Endocr Metab Disord.* 2003;4(2):195-206. [PMID: 12766548](https://pubmed.ncbi.nlm.nih.gov/12766548/)

### Also on this topic

The same subject at other levels of depth.

- **Student handout:** [Magnesium Disorders: Student Handout](https://urinenephrology.org/student-resources/electrolyte-acid-base/magnesium-disorders-student-handout.html)


---

[Website version](https://urinenephrology.org/mastery/electrolytes-advanced/magnesium.html) · Markdown synchronized October 3, 2026.